Sector News

GlaxoSmithKline taps TARA’s ‘beating-heart-on-a-chip’ to simulate cardiac drug responses

August 12, 2019
Life sciences

Using engineered tissues to create a small working simulacrum of a beating heart, researchers at GlaxoSmithKline and TARA Biosystems aim to predict how the body’s cardiovascular system responds to potential therapies.

TARA’s 3D “heart-on-a-chip” system was able to accurately replicate human drug responses, according to a study published in the journal Toxicological Sciences—something that’s been difficult to achieve with in vitro testing or animal models.

With cardiac toxicity affecting almost half of new medicine recalls, effective preclinical testing and safety assessments are essential, the two companies said.

To construct the tissues, TARA took induced pluripotent stem cells and cultivated them into cardiomyocytes, the muscle cells of the heart. By directing the cells’ differentiation and conditioning them with electrical fields over a period of weeks, researchers were able to build distinct tissues that mimic the contractions of the atria and ventricles, as well as their drug responses and gene expression. Their work was published earlier this year in Cell.

By measuring how strongly the engineered tissues contract when dosed with different drugs, the companies can get a sense of how potential therapies may affect a healthy human heart’s ability to pump blood to the body. Researchers also saw that the drugs acted along the same molecular pathways seen in human heart tissue.

Additionally, by using stem cells derived from certain patients, the platform could also be used to model different heart diseases, according to TARA.

Currently, GSK is applying a panel of drugs with known efficacy and toxicity profiles, in order to compare TARA’s platform with other preclinical drug screening methods. These include its responses to blood pressure medications, such as Procardia (nifedipine), Isuprel (isoproterenol) and Digox (digoxin), as well as drugs being studied in heart failure, like dobutamine and omecamtiv.

In January, TARA launched a drug discovery collaboration with Insilico Medicine, focused on cardiovascular disease and cardiac muscle aging. The two aim to combine Insilico’s AI-powered discovery engine with TARA’s tissue models for testing.

By: Conor Hale

Source: Fierce Biotech

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”